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abstract
PURPOSE Biologic heterogeneity is a feature of diffuse large B-cell lymphoma (DLBCL), and the existence of
a subgroup with poor prognosis and phenotypic proximity to Burkitt lymphoma is well known. Conventional
cytogenetics identiﬁes some patients with rearrangements of MYC and BCL2 and/or BCL6 (double-hit lym-
phomas) who are increasingly treated with more intensive chemotherapy, but a more biologically coherent and
clinically useful deﬁnition of this group is required.
PATIENTS AND METHODS We deﬁned a molecular high-grade (MHG) group by applying a gene expression–
based classiﬁer to 928 patients with DLBCL from a clinical trial that investigated the addition of bortezomib to
standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. The
prognostic signiﬁcance of MHG was compared with existing biomarkers. We performed targeted sequencing of
70 genes in 400 patients and explored molecular pathology using gene expression signature databases.
Findings were validated in an independent data set.
RESULTS The MHG group comprised 83 patients (9%), with 75 in the cell-of-origin germinal center B-cell-like
group. MYC rearranged and double-hit groups were strongly over-represented in MHG but comprised only one
half of the total. Gene expression analysis revealed a proliferative phenotype with a relationship to centroblasts.
Progression-free survival rate at 36 months after R-CHOP in the MHG group was 37% (95% CI, 24% to 55%)
compared with 72% (95% CI, 68% to 77%) for others, and an analysis of treatment effects suggested a possible
positive effect of bortezomib. Double-hit lymphomas lacking the MHG signature showed no evidence of worse
outcome than other germinal center B-cell-like cases.
CONCLUSION MHG deﬁnes a biologically coherent high-grade B-cell lymphoma group with distinct molecular
features and clinical outcomes that effectively doubles the size of the poor-prognosis, double-hit group. Patients
with MHG may beneﬁt from intensiﬁed chemotherapy or novel targeted therapies.
J Clin Oncol 37:202-212. © 2018 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Aggressive B-cell non-Hodgkin lymphomas, including
diffuse large B-cell lymphoma (DLBCL) and Burkitt
lymphoma (BL), comprise a heterogeneous class of
related malignancies for which response and survival
on standard treatment vary substantially, with signiﬁ-
cantly worse outcomes in some subtypes. DLBCL
incidence is high and carries a signiﬁcant disease
burden,1 whereas BL is a distinct and highly pro-
liferative entity that requires substantially more
intensive chemotherapy. Within DLBCL, the cell-of-
origin (COO) variants germinal center B-cell-like (GCB)
and activated B-cell-like (ABC) DLBCL have been
deﬁned by gene expression patterns.2 These have
different underlying molecular pathology and prog-
nosis, but internal heterogeneity in their genetic and
phenotypic features indicates that further stratiﬁcation
is necessary for precision treatment.3
Several groups recently have considered DLBCL
stratiﬁcation by using integrated genetic information,
providing prognostic models,4 or separating patients
further into smaller subgroups on the basis of shared
genetic features.5,6 Earlier work identiﬁed patients with
key chromosomal rearrangements of MYC and BCL2
and/or BCL6 genes (double and triple hits) that cor-
related with poor response to standard therapy.7,8MYC
rearrangement (MYC-R) is a feature shared with BL,
and such tumors often have some BL-like genomic
features and patterns of gene expression.9,10 Gene
expression proﬁling also has been used to distinguish
DLBCL and BL,11,12 but intermediate categories of
high-grade DLBCL remain, including those with
double hits, those whose overall pattern of gene ex-
pression resembles that of BL, and those that strongly
express both MYC and BCL213 proteins, for which the
optimal group deﬁnition and treatment choices are still
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unclear. These MYC and BL-related groups do not feature
clearly in the recent genetic classiﬁcations,5,6 but they are
present in two new WHO designations as high-grade B-cell
lymphoma with MYC and BCL2 and/or BCL6 translocation
and high-grade B-cell lymphoma not otherwise speciﬁed.14
The difﬁculty in deﬁning the optimum approach to this
group is partly explained by the low frequency of groups
such as double-hit lymphomas, and the absence of a clear
biologic deﬁnition. With the beneﬁt of a large clinical trial
data set, we suggest here a unifying deﬁnition of a mo-
lecular high-grade (MHG) class that is based on gene
expression and propose that it should form part of our
evolving understanding of DLBCL.
The Randomized Evaluation of Molecular-Guided Therapy
for DLBCL With Bortezomib (REMoDL-B) clinical trial15
tested standard therapy for DLBCL (rituximab, cyclo-
phosphamide, doxorubicin, vincristine, and prednisolone
[R-CHOP]) against its combination with the proteasome
inhibitor bortezomib (RB-CHOP). The hypothesis was that
bortezomib indirectly inhibits the nuclear factor kappa-
light-chain-enhancer of activated B cells pathway be-
lieved to be speciﬁcally active in the ABC variant.16 We
present our analysis of the trial data focused on the MHG
group by showing that a biologically coherent and dis-
tinctive group with signiﬁcantly poorer prognosis can be
identiﬁed and validated in independent data. We suggest
that this group should be targeted in the future with pre-
cision medicine approaches.
PATIENTS AND METHODS
Data Set Summary
A total of 928 patients treated in the REMoDL-B trial15 (Data
Supplement) were included in this retrospective study.
Genome-wide gene expression data were available for all
patients from formalin-ﬁxed parafﬁn-embedded tissue
samples. A subset of 400 patient samples was sequenced
for a 70-gene panel, chosen by known relevance to DLBCL,
with HaloPlexHS (Agilent Technologies, Santa Clara, CA)
target enrichment and HiSeq 4000 (Illumina, San Diego,
CA) sequencing, and analyzed for somatic mutations (Data
Supplement). Furthermore, for the purpose of comparison
with other known biomarkers, a subset of 360 patient
samples was tested for MYC, BCL2, and BCL6 chromo-
somal rearrangements with ﬂuorescent in situ hybridization
assays, and a subset of 355 samples was tested for MYC
and BCL2 protein expression with immunohistochemistry
using tissue microarrays. Clinical features, treatment,
progression status, and follow-up data (median,
30 months) were available for all patients. The available
data are summarized in Figure 1, and full details are
provided in the Data Supplement. Methodological detail in
addition to that given here is provided in the Data
Supplement.
COO Classiﬁcation and the MHG Subgroup
Gene expression data–based COO classiﬁcation was per-
formed in the trial with the DLBCL automatic classiﬁer17 in
real-time for random assignment to R-CHOP or RB-CHOP
in the second to sixth treatment cycles. For this analysis, the
COO classiﬁcation was repeated with the same method to
take advantage of higher-quality samples that became
available for some patients after randomization and im-
proved data normalization over the complete trial data set.
The overall concordance between this retrospective COO
classiﬁcation (255 ABC, 543 GCB, and 130 unclassiﬁed
[UNC]) and the real-time prospective classiﬁcation (244
ABC, 475 GCB, and 199 UNC) from the trial randomization
was 87%. The main change between prospective and
retrospective COO DLBCL automatic classiﬁcation was the
reduction of UNC patients who were reassigned to ABC and
GCB in the retrospective classiﬁcation. The classiﬁcation
shift between GCB and ABC was low (4.5%). Full details of
the prospective and retrospective classiﬁcations are pro-
vided in the Data Supplement.
Our previous work had shown that patients with DLBCL with
a BL-like pattern of gene expression had poor prognosis.18
Accordingly, we applied the gene expression classiﬁer
Clinical Data
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FIG 1. Data set summary. The analysis included 928 patients from the Randomized Evaluation of Molecular-
Guided Therapy for Diffuse Large B-Cell Lymphoma With Bortezomib (REMoDL-B) clinical trial. All had full
clinical data (diagnostic variables, treatment, treatment response, progression status, and follow-up time) and
whole-genome expression proﬁling assayed by the DASL version 4 array (Illumina, San Diego, CA). A subset of
400 patients was analyzed for somatic mutations with a targeted 70-gene panel. In addition, 360 patients were
tested for MYC, BCL2, and BCL6 rearrangements by ﬂuorescent in situ hybridization (FISH), and 355 patients
were tested for MYC and BCL2 protein expression with immunohistochemistry (IHC).
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developed in that work to REMoDL-B patients, using all
those with BL and DLBCL in our local database for the
normalization background, to deﬁne the MHG class. Of
note, the deﬁnition of the MHG class was determined in
previous work with an earlier data set and was not trained or
determined in any way from the REMoDL-B trial data.
Conventional diagnosis of all identiﬁed patients with MHG
was checked for this study (Data Supplement) and in-
dicated that this group had DLBCL by morphology and
immunophenotype, thus excluding the possibility of con-
tamination with patients with BL.
External Validation
Although the MHG group was deﬁned independently
of the clinical trial data, we validated it further on
another independent and recently published data set4
(European Genome-Phenome Archive study accession
EGAS00001002606) by using the core set of 624 pa-
tients whose gene expression proﬁles were examined in
that study by RNA sequencing. Adaptation of our clas-
siﬁer to these data was straightforward because the
classiﬁer was designed and tested18 for cross-platform
applicability. We note, however, that there are no di-
agnoses of BL in this data set, which could have a minor
effect on the overall normalization, and that in this data
set four classiﬁer genes (BMP7, TCL6, SOX11, and
C7orf10) had very low estimated expression levels from
the RNA sequencing data. The classiﬁer, therefore, was
retrained using the original training data,18 with the gene
set reduced by these four genes for application to this
data set. COO classiﬁcation was that provided by the
authors. Analysis of mutation frequencies in this data set
used the 150 identiﬁed driver genes from the original
article ﬁltered by at least 5% mutation frequency in at
least one subgroup and signiﬁcantly different frequency
(Fisher’s exact P, .05) between any two groups of MHG,
GCB, and ABC.
Statistical Analysis
All survival analyses were carried out using the survival
package in R (https://cran.r-project.org), using single-
factor and multivariable Cox proportional hazards re-
gression models and likelihood ratio tests. Associations in
count data related to clinical variables, chromosomal
rearrangements, mutations, and so forth were analyzed
with Fisher’s exact test. For continuous variables, dif-
ferences between groups were tested with Mann-Whitney
U or t tests as appropriate. All quoted P values are two-
sided.
RESULTS
Deﬁnition and Clinical Outcome of MHG Lymphoma
Our gene expression classiﬁer assigned 83 REMoDL-B
patients as MHG (9%; Fig 2). Seventy-ﬁve patients in the
MHG group (90%) were within the original GCB group
(Fig 2A) and were considered separately in the subsequent
analysis, with GCB, ABC, and UNC referring (unless oth-
erwise stated) to patients within those classes but not
identiﬁed as MHG. A full analysis of associations between
the COO and MHG groups and other clinical prognostic
factors (Data Supplement) showed that MHG has a signif-
icantly higher International Prognostic Index19 (IPI; P =
.004), tumor bulk (P = .007), and stage (P = .06). Median
lactate dehydrogenase levels in patients with MHG were
higher by almost 1.5-fold (P , .001), which reﬂects higher
proliferation and cell turnover.
Signiﬁcant differences in progression-free survival (PFS)
and overall survival were observed between MHG and other
COO groups. After treatment with R-CHOP, three-year PFS
rate estimates were 37% for MHG, 78% for GCB, 64% for
ABC, and 65% for UNC (Fig 2B-2E). Multivariable Cox
proportional hazards regression models were used to as-
sess the additional prognostic information provided by the
MHG group (Table 1). The ﬁrst model showed that MHG
provided additional information to that from clinical vari-
ables as encapsulated in the standard IPI (P , .001), and
the second showed that MHG provided additional in-
formation to relevant clinical variables from the IPI and
other COO groups. In the RB-CHOP arm (Fig 2C), the
results in the MHG group showed a nonsigniﬁcant trend
toward improvement (3-year PFS rate, 58%), which pro-
vides possible evidence of a positive effect of bortezomib
despite the small number of patients (P = .08 Fig 2E).
Molecular Characteristics of the MHG Group
To clarify the molecular characteristics of the MHG group,
we augmented the trial data set with 70 patients with
conﬁrmed BL from a previous study18 that used the same
platform to measure gene expression (Data Supplement)
and performed differential gene expression and gene
expression signature analyses. Differential expression
analysis (Data Supplement) revealed that BL is charac-
terized by a large number of upregulated genes compared
with both GCB (2,483 genes) and MHG (1,784 genes). In
contrast, the comparison of MHG and GCB revealed
only 382 upregulated genes. Downregulated genes had
a similar pattern, and together, these ﬁgures indicate
that MHG is an intermediate group but closer to GCB
than to BL.
Gene signature databases were used to obtain functional
insights into MHG biology (Fig 3). Figure 3B shows the
results from a compact and lymphoma-enriched data-
base20 for patients with mutation data available (an analysis
of all patients revealed the same patterns). To simplify the
analysis, signatures were ﬁrst clustered, each cluster was
named according to the function of its constituent signa-
tures and their genes, and expression values were plotted in
the heat map for a chosen representative signature for each
cluster. This shows that MHG and BL share high expression
of signatures that contain cell cycle genes, ribosome bio-
genesis, MYC overexpression, and TCF3 targets, which
204 © 2018 by American Society of Clinical Oncology Volume 37, Issue 3
Sha et al
Downloaded from ascopubs.org by 90.205.25.229 on January 25, 2019 from 090.205.025.229
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
suggests a shared proliferative phenotype. Of note, BL and
MHG showed high expression of the germinal center
centroblast (dark zone) signature and lower expression of
the germinal center centrocyte (light zone) signature rel-
ative to other subgroups.21 (We note that some patients with
ABC showed relatively high expression of both centrocyte
and centroblast signatures, which is likely due to cell cycle
genes in the latter signature and may reﬂect proliferative
ABCs that resemble plasmablasts.) Signatures that
show low expression in MHG and BL include those involved
with MHC class II, stromal, and immune response. Of note,
our differential expression analysis shows that FOXP1,
which has a number of functions, including the control of
apoptotic genes, immune response signatures, and MHC
class II,22,23 is upregulated in BL and MHG relative to GCB.
A more comprehensive gene set enrichment analysis24
using MSigDB25 to analyze the differential expression
gene lists (Data Supplement) conﬁrmed these results.
Somatic mutation data (Fig 3A; Data Supplement) revealed
the expected associations for the ABC and GCB groups,26,27
with the former enriched for mutations in MYD88, PIM1,
CD79B, BTG2, TBL1XR1, and PRDM1 and the latter for
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FIG 2. Retrospective Randomized Evaluation of Molecular-Guided Therapy for Diffuse Large B-Cell LymphomaWith Bortezomib (REMoDL-B) trial analysis
with the molecular high-grade (MHG) group. (A) Number of REMoDL-B patients with standard cell-of-origin (COO) classiﬁcation (inner circle) and with
MHG patients separated into a new class (outer circle). For the latter, the overall distribution between classes is shown in the histogram. (B) Progression-
free survival (PFS) curves for rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)–treated patients by classiﬁcation, with
MHG as a separate class. (C) As in (B) but for patients treated with R-CHOP with the proteasome inhibitor bortezomib (RB-CHOP). (D) As in (B), but overall
survival (OS) for all patients. (E) Progression-free survival for MHG patients separated by treatment. P values given for overall difference in survival are from
the likelihood ratio test and for individual groups with reference to the best-surviving group from a Cox proportional hazards regression model. ABC,
activated B-cell-like; GCB, germinal center B-cell-like; HR, hazard ratio; NA, not applicable; UNC, unclassiﬁed.
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BCL2, EZH2, KMT2D, and MEF2B. MHG had signiﬁcantly
higher mutation frequencies than GCB in KMT2D, BCL2,
MYC, and DDX3X, whereas some frequent mutations in
GCB (eg, B2M, SGK1, NFKBIA) were rare in MHG. These
mutation patterns share some features (MYC, DDX3X) but
not all (KMT2D, BCL2) with BL.28,29 In a similar vein, MHG
did not have a high rate of mutation of TCF3 or its negative
regulator ID3 typical of BL.28-30 Expression of ID3 was
reduced in MHG compared with BL, whereas TCF3 was
expressed at similar levels (Data Supplement), which
suggests that alternative regulatory mechanisms operate
for these genes in MHG.
Aberrant somatic hypermutation31 probably explains the
high mutation rates of MYC and BCL2 in MHG. Of note,
MYCmutations are associated withMYC-R within the MHG
class (12 of 16 rearranged cases also are mutated) but not
TABLE 1. Multivariable Cox Proportional Hazards Regression Model Analysis of Progression-Free Survival
Multivariable Model No. of Patients No. Progressing (%) HR (95% CI) P
MHG and IPI*
MHG
Non-MHG 845 216 (25.6) Reference
MHG 83 43 (51.8) 2.29 (1.64 to 3.19) , .001
IPI
Low (0-1) 246 43 (17.5) Reference
Intermediate (2-3) 517 143 (27.7) 1.66 (1.18 to 2.33) .004
High (4-5) 165 73 (44.2) 2.83 (1.93 to 4.14) , .001
Treatment
R-CHOP 469 139 (29.6) Reference
RB-CHOP 459 120 (26.1) 0.87 (0.68 to 1.11) .268
Molecular subtype and clinical variables†
Molecular subgroup
GCB 468 99 (21.2) Reference
ABC 249 73 (29.3) 1.44 (1.06 to 1.95) .019
UNC 128 44 (34.4) 1.59 (1.11 to 2.28) .011
MHG 83 43 (51.8) 2.79 (1.94 to 4.03) , .001
Age, years
, 60 332 96 (28.9) Reference
$ 60 596 163 (27.3) 0.93 (0.72 to 1.19) .554
Stage
I/II 286 62 (21.7) Reference
III/IV 642 197 (30.7) 1.39 (1.03 to 1.87) .032
Extra nodal involvement
No 407 97 (23.8) Reference
Yes 521 162 (31.1) 1.10 (0.84 to 1.43) .498
LDH, U/L
, 500 589 131 (22.2) Reference
$ 500 339 128 (37.8) 1.58 (1.23 to 2.04) , .001
Treatment
R-CHOP 469 139 (29.6) Reference
RB-CHOP 459 120 (26.1) 0.87 (0.68 to 1.12) .274
Abbreviations: ABC, activated B-cell-like; GCB, germinal center B-cell-like; HR, hazard ratio; IPI, International Prognostic Index; LDH, lactate
dehydrogenase; MHG, molecular high-grade; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; RB-CHOP,
rituximab and bortezomib plus cyclophosphamide, doxorubicin, vincristine, and prednisone; UNC, unclassiﬁed.
*Model 1 demonstrates the prognostic effect of the MHG group in addition to the current standard IPI on the basis of clinical variables.
†Model 2 demonstrates the prognostic effect of the MHG group in the context of cell-of-origin subgroups and the separate prognostic clinical
factors that make up the IPI. Because patients with an Eastern Cooperative Oncology Group performance status. 2 were considered ineligible
for the trial, Eastern Cooperative Oncology Group performance status was not included as a factor in the model.
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in other classes (only one of 12 rearranged cases is mu-
tated), which suggests that MYC-Rs outside MHG are bi-
ologically different.
Comparison With Other Established Biomarkers
We assessed the relationship of the MHG group to biomarkers
commonly used to characterize related high-riskDLBCL (Fig 4).
Of the 360 patients for whom ﬂuorescent in situ hybridization
data were available, 51 (14%) had MYC-R, and 35 of these
(67%) were double-hit (also with BCL2 and/or BCL6 rear-
rangement). MostMYC-Rs (75%) were in theMHG group, with
the remainder lying in GCB and UNC (MHG enrichment by
Fisher’s exact test,P, .001), but only 48.6%and36.1%of the
MHG group wereMYC-R and double-hit, respectively (Fig 4A).
(Continued). (SHM) target genes fromSchmitz et al.6 (B)Heatmap of gene expression signatures (bottom) and associatedmutations (top; limited to geneswith
mutation frequency. 5% in at least one group and signiﬁcantly different [P, .05] between any two groups of MHG, GCB, and ABC). The heat map shows the
mean gene expression level (red = high to blue = low) over genes in the chosen signature cluster representative and is augmented in 70 patients with Burkitt
lymphoma (BL) for comparison of gene expression patterns. The left-side bar chart (top) recapitulates the incidence of the corresponding mutations and their
distribution among subgroups. Fb, ﬁbroblast; NA, not applicable; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cell; NK, natural killer cell.
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Both patients with MYC-R and patients with double-hit
status had worse PFS than those who were MYC-normal
(Data Supplement). Furthermore, irrespective of MYC-R or
double-hit status, the MHG group had a lower PFS than the
GCB group (Figs 4B and 4C). Of note, although patient
numbers were small in the GCB group, there is no evidence
of an effect of MYC-R or double-hit status on PFS, but in
MHG, both confer even lower PFS. A comparative gene
expression analysis (Data Supplement) showed no
differentially expressed genes between MYC-R and MYC-
normal within the MHG group but did show 54 differ-
entially expressed genes between MYC-R MHG and
MYC-R GCB, which supports the biologic distinctiveness
of MHG.
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A subset of 355 samples also was investigated for MYC and
BCL2 protein expression by IHC to identify cases of double-
expressors, and at the mRNA level all trial samples were
assessed for combined high expression of MYC and BCL2.
In contrast to double-hits, double-expressors were found in
signiﬁcant numbers in all groups, including ABC (Figs 4D
and 4F). Although protein expression was correlated with
mRNA level (Data Supplement), the immunohistochemistry-
identiﬁed double-expressor group did not show signiﬁcant
PFS separation in this study (Data Supplement). However,
patients with double-expressor status deﬁned by mRNA
level where data covered all samples had a signiﬁcantly
lower PFS and further separated patients within subtypes
(Fig 4E; Data Supplement). Patients with MHG lymphoma
nevertheless showed worse outcome regardless of double-
expressor status relative to ABC and GCB subgroups (Fig
4E). Details of the distribution of all biomarkers in the COO
and MHG groups are provided in the Data Supplement as is
a full analysis of the prognostic effects of these biomarkers.
External Validation of the MHG Group
Our analysis of the external validation data set4 is shown in
Fig 5. Seventy-two of patients (11.5%) were classiﬁed as
MHG, and consistent with the ﬁrst data set (Fig 2A), the
majority (82%) of the MHG group was derived from the
GCB subtype (Fig 5A). The MHG group showed similar
associations with clinical variables (Data Supplement) and
similar mutation spectrum in the REMoDL-B and validation
data sets (Figs 5C and 5D; Data Supplement). Gene ex-
pression signature analysis in the validation data set (Fig
5D), which used our signature set from Figure 3, or the
authors’ signature set used in their original article (Data
Supplement), showed the same proliferation and
centroblast-related biology. MHG had a higher risk in these
authors’ prognostic model compared with the remaining
GCBs (P , .001) and a poor outcome, with a signiﬁcantly
lower overall survival than the other GCBs (P , .001; Fig
5B).
DISCUSSION
We have deﬁned the MHG group of patients with DLBCL
that identiﬁes a poor-risk subgroup primarily within the
conventional GCB COO class. This encompasses most
patients with double-hit lymphoma but extends the mo-
lecular identiﬁcation to more than double the size of
this poor-prognosis group, and signiﬁcantly, this also re-
ciprocally enriches the remaining patients with GCB DLBCL
as a very good–prognosis group. Our analysis indicates that
MHG is a robust and distinct group that is identiﬁable in
independent data sets. MHG lymphoma has similarity in
gene expression to both BL and GCB-DLBCL but with
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immunophenotype in keeping with DLBCL rather than
BL and a characteristic pattern of genomic mutation. The
poor prognosis for this group when treated with R-CHOP
suggests that different approaches are required: either
intensiﬁcation of the type increasingly used for the
double-hit lymphomas or, potentially, targeted agents
that may preferentially affect more rapidly cycling
cells. Gene expression patterns indicate that MHG has
a highly proliferative phenotype and shares features with-
centroblasts of the germinal center dark zone in contrast to
the centrocyte or light zone features of other GCBs.21
Recent analyses have suggested new taxonomies of DLBCL
on the basis of genetic characteristics.5,6 Whereas Schmitz
et al6 used a data set focused strongly on the ABC and UNC
COO groups, where the MHG group would be under-
represented, Chapuy et al5 commented on the genetic
complexity of MYC and BCL2 dysregulation that is repre-
sented in more than one of their clusters. Although there
are limitations to our genetic data, which are based on
a small gene panel without germline control and do not
include copy number and other structural variations, our
data reinforce the distinction among BL, MHG, GCB, and
ABC. However, the reproducibly poor outcome in the MHG
group suggests that in this case, the gene expression state
captures biologically and clinically important features that
are not readily identiﬁed from the use of genetics alone.
Indeed, our mutation data suggest that the expression state
may result from a number of different genetic drivers, in-
cluding MYC and BCL2 rearrangements, epigenetic effects
related to mutations in KMT2D32 and EZH2, and mutations
that affect other pathways. Although only a small number of
MYC-Rs were identiﬁed outside the MHG group, their out-
comes were similar to those of the other GCBs. Our data also
indicate thatMYCmutation levels ofMYC-Rs differ between
MHG and other groups, which suggests a different biology
that could be related to different translocation partners.33
Evidence from the trial of a possible positive effect of
bortezomib in the MHG group, although lacking statistical
power, suggests a potential treatment option for this highly
aggressive subtype. In future studies, it will be important to
explore this mechanism, which seems unlikely to be me-
diated by the nuclear factor kappa-light-chain-enhancer of
activated B cells pathway that is not believed to be active in
GCB or MHG tumors.
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